Coherus Biosciences (NASDAQ:CHRS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.
Insider & Institutional Ownership
95.2% of Coherus Biosciences shares are owned by institutional investors. Comparatively, 86.2% of Biogen shares are owned by institutional investors. 18.2% of Coherus Biosciences shares are owned by company insiders. Comparatively, 0.4% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Coherus Biosciences and Biogen, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Coherus Biosciences currently has a consensus price target of $32.57, suggesting a potential upside of 75.59%. Biogen has a consensus price target of $270.09, suggesting a potential upside of 21.00%. Given Coherus Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Coherus Biosciences is more favorable than Biogen.
Risk and Volatility
Coherus Biosciences has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, Biogen has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
Earnings & Valuation
This table compares Coherus Biosciences and Biogen’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coherus Biosciences||$1.56 million||829.57||-$209.34 million||($3.22)||-5.76|
|Biogen||$13.45 billion||3.06||$4.43 billion||$26.20||8.52|
Biogen has higher revenue and earnings than Coherus Biosciences. Coherus Biosciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
This table compares Coherus Biosciences and Biogen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About Coherus Biosciences
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.